Frequently referred to as wonder drugs, GLP-1s are increasingly recognized for their potential well beyond the treatment of diabetes and obesity alone 1
Tirzepatide (Mounjaro) (Note: Technically a dual GLP-1/GIP agonist) Approved for diabetes, with weight loss benefits under clinical evaluation for obesity
[DOI] [PubMed] [Google Scholar] 84.Nagasu H., Sogawa Y., Kidokoro K., Itano S., Yamamoto T., Satoh M., Sasaki T., Suzuki T., Yamamoto M., Wigley W.C., et al
While the medication is usually covered for people with diabetes, it is still not typically covered as a weight-loss medication
As a result, acetaldehyde levels may remain higher in women for longer, increasing inflammation and oxidative stress
If your insurance plan covers oral semaglutide, your out-of-pocket expenses may be reduced to a copay or coinsurance